Related Experiment Video
Updated: May 12, 2026
Multiplex PCR Assay for Typing of Staphylococcal Cassette Chromosome Mec Types I to V in Methicillin-resistant Staphylococcus aureus
Published on: September 5, 2013
MET and SLFN11 as a Players in the SCLC Molecular Subtyping Game
Anna Grenda1, Natalia Galant1, Aleksandra Łomża-Łaba1
1Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Jaczewskiego 8, 20-954 Lublin, Poland.
Abstract:
The possibilities of small-cell lung cancer (SCLC) therapy were strictly limited for years, leading to high patient mortality rates. New approaches to SCLC treatment are being proposed, including chemoimmunotherapy. However, biomarkers enabling appropriate personalization of therapy in SCLC patients have not been identified yet. Even though molecular subtyping (ASCL1, NEUROD1, POU2F3, and YAP1) seems pivotal in the management of SCLC, expression of other genes might be potentially valuable during patients' stratification. Due to their crucial role in tumorigenesis and SCLC invasiveness, benefits arising from MET and SLFN11 gene evaluation are suggested. Our study was designed to evaluate the relationship between the mRNA expression of these genes and chemoimmunotherapy efficacy in SCLC patients. A total of 35 patients with extensive-stage SCLC (ES-SCLC) treated with first-line chemoimmunotherapy were involved in the study. mRNA expression of MET and SLFN11 genes was evaluated using the RT-qPCR technique in FFPE tissue collected from all patients. Molecular results were correlated with clinicopathological features and outcome of disease (OS, PFS). We detected SLFN11 expression in 60% (21 of 35) of the samples. SLFN11 expression was higher in patients with longer PFS (p = 0.05) and with the T4 feature in the TNM scale (p = 0.08). MET mRNA was expressed in all FFPE tissues. We observed that risk of progression and death was higher in patients with higher expression of MET mRNA (p = 0.06 and p = 0.04, respectively). Our study showed that MET and SLFN11 expression might serve as additional biomarkers for prediction of chemoimmunotherapy efficacy in ES-SCLC patients.
Insights
Biomarkers MET and SLFN11 show promise for predicting chemoimmunotherapy effectiveness in extensive-stage small-cell lung cancer (SCLC). Higher SLFN11 expression correlated with longer progression-free survival, while higher MET expression indicated increased risk of progression and death.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Small-cell lung cancer (SCLC) therapy options have been limited, resulting in high mortality.
- Chemoimmunotherapy offers a new approach, but personalized treatment requires reliable biomarkers.
- Current molecular subtyping of SCLC does not fully address patient stratification needs.
Purpose of the Study:
- To investigate the potential of MET and SLFN11 gene expression as predictive biomarkers for chemoimmunotherapy efficacy in extensive-stage SCLC (ES-SCLC).
- To correlate mRNA expression levels of MET and SLFN11 with clinical outcomes, including overall survival (OS) and progression-free survival (PFS).
Main Methods:
- Retrospective analysis of 35 ES-SCLC patients treated with first-line chemoimmunotherapy.
- Quantitative real-time PCR (RT-qPCR) to measure MET and SLFN11 mRNA expression in FFPE tumor tissues.
- Correlation of gene expression data with clinicopathological features and patient outcomes (OS, PFS).
Main Results:
- SLFN11 expression was detected in 60% of patients and was associated with longer PFS (p=0.05) and T4 stage (p=0.08).
- MET mRNA was universally expressed. Higher MET expression correlated with an increased risk of progression (p=0.06) and death (p=0.04).
Conclusions:
- MET and SLFN11 mRNA expression levels may serve as valuable biomarkers for predicting chemoimmunotherapy response in ES-SCLC patients.
- These findings could aid in personalizing SCLC treatment strategies.
- Further validation in larger cohorts is warranted to confirm the clinical utility of these biomarkers.
